Cybin adds several experts in mental health to its Clinical Advisory Board.

People under the influence of psilocybin — the active component of magic mushrooms — report having more profound and original thoughts, but tend to score lower on cognitive tests of creative ability, according to new research published in Translational Psychiatry.

WHY AREN’T PEOPLE with depression prescribed magic mushrooms instead of Zoloft or Prozac?

Digital therapeutics is the wave of the future in healthcare. The psychedelic drug industry is at the forefront for this new tech.

Sen. Cory Booker says that President Joe Biden is already where he needs to be to get a bill to end federal marijuana prohibition enacted into law—even if he personally opposes legalization. Confusion about the president’s position comes down to semantics, the senator indicated.

Utilizing Speak Ai’s technology, iSTRYM will provide-AI-driven intelligence to help therapists identify the most efficient and efficacious outcomes for patients of psychedelic assisted psychotherapy

Cybin prepares two drug candidates, CYB003 and CYB004 for Investigational New Drug applications.

A New England Journal of Medicine study found CMPS’s COMP360 psilocybin therapy performed better than the leading antidepressant.

Novamind increases its strategic investment in Bionomics Limited, in support of its plans for a Phase IIb clinical trial for PTSD.

Mydecine commences screening psilocybin-based drug candidates.